DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
Dexcom shares sank more than 40% on Friday, their steepest decline ever. The company reported disappointing revenue on Thursday and lowered its full-year guidance. Executives blamed a restructuring of ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results